Radiation Oncology Market Size, Share & Trends Analysis Report By Type (External Beam Radiation Therapy, Internal Beam Radiation Therapy), By Technology, By Application, By Region, And Segment Forecasts, 2023 - 2030

Radiation Oncology Market Size, Share & Trends Analysis Report By Type (External Beam Radiation Therapy, Internal Beam Radiation Therapy), By Technology, By Application, By Region, And Segment Forecasts, 2023 - 2030

Radiation Oncology Market Growth & Trends

The global radiation oncology market is expected to reach USD 21.14 billion by 2030, registering a CAGR of 12.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the global rise in cancer burden, the growing geriatric population, and supportive reimbursement programs undertaken by the government and private organizations. Furthermore, the increasing technological innovation and advancement in radiotherapy offer lucrative opportunities for market growth.

The world is witnessing an increasing prevalence of cancer cases which is the key factor driving the radiation oncology market growth. For instance, according to Globocan, in 2020, more than 20.0 million people were diagnosed with cancer, and 10.0 million died of cancer. Moreover, the aging population is at high risk of cancer due to a weak immune system and comorbid conditions; thereby, the rising geriatric population further fuels market growth. For instance, in 2020, according to WHO estimates, the global geriatric population was approximately 1.0 billion and is expected to reach 2.1 billion by 2050.

Extensive research activities for the development of novel radiotherapy techniques and multidisciplinary therapeutic approaches are expected to lead to an increased survival rate and a more favorable prognosis of cancer. For instance, in December 2022, Elekta Unity demonstrated MR-Linac use for pancreatic tumors, where the first-ever patient was treated with new advanced radiotherapy motion management.

Similarly, in June 2020, Isoray signed a research agreement with the University of Cincinnati Physicians Company to study neck and head cancer treatment. The companies will evaluate the efficacy of Keytruda along with Cesium-131 post-surgical resection. Using such medical isotopes for cancer treatment may boost the research in developing a new target-specific radiation therapy system by understanding disease complexity & patients' need, thereby widening the opportunity in the market.

Furthermore, supportive reimbursement and regulatory policies for radiation therapy are also expected to drive the radiation oncology market growth. For instance, in July 2021, the Centers for Medicare and Medicaid Services (CMS) developed a new Radiation Oncology Payment Model (RO-APM) for the diagnosis of cancer and radiotherapy services. It enhances the quality of care of the patients and reduces the annual Medicare expenditure.

Radiation Oncology Market Report Highlights

  • By type, the external beam radiation therapy (EBRT) segment accounted for a 64.53% share of the radiation oncology market in 2022 due to the rapid technological advancement, and increased adoption in the treatment of various types of cancers
  • Based on technology, in 2022 intensity-modulated radiotherapy (IMRT) segment dominated the market due to the increased availability of technologically advanced IMRT's in countries with unmet treatment needs. However, brachytherapy is estimated to be the fastest-growing segment during the forecast period
  • In 2022, EBRT segment held the highest market share in the application space. Moreover, EBRT segment is also anticipated to maintain its dominance during the forecast period
  • North America dominated the global market in 2022 owing to the factors such as the increase in new cancer cases, high awareness among healthcare professionals about advanced radiotherapy, and better healthcare access in the region
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1 Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline:
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 List Of Secondary Sources
1.8 List Of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Market Definitions
3.3 Key Opportunities Prioritized
3.4 Market Dynamic Analysis
3.4.1 Rising Adoption Of Radiotherapy
3.4.2 Technological Advancements In Radiotherapy
3.4.3 Rising Prevalence Of Cancer
3.4.4 Increase In Healthcare Expenditure
3.4.5 Increasing APPLICATION OF Radiopharmaceuticals
3.5 Market Restraint Analysis
3.5.1 Lack Of Skilled Radiotherapy Professionals
3.5.2 Inadequate Radiation Infrastructure
3.5.3 Adverse Effects Of Radiotherapy
3.6 Business Environment Analysis
3.6.1 SWOT Analysis; By Factor (POLITICAL & LEGAL, Economic And Technological)
3.6.2 Porter’s Five Forces Analysis
Chapter 4 Radiation Oncology Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)
4.1 Radiation Oncology Market: Type Movement Analysis
4.2 External Beam Radiation Therapy
4.2.1 External Beam Radiation Therapy Market, 2018 - 2030 (USD Million)
4.2.2 Electron-Emitting High Energy Linear Accelerators
4.2.2.1 Electron-Emitting High Energy Linear Accelerators Market, 2018 - 2030 (USD Million)
4.2.3 Compact Advanced Radiotherapy Systems
4.2.3.1 Compact Advanced Radiotherapy Systems Market, 2018 - 2030 (USD Million)
4.2.3.2 Cyberknife
4.2.3.2.1 Cyberknife Market, 2018 - 2030 (USD Million)
4.2.3.3 Gamma Knife
4.2.3.3.1 Gamma Knife Market, 2018 - 2030 (USD Million)
4.2.3.4 Tomotherapy
4.2.3.4.1 Tomotherapy Compact Market, 2018 - 2030 (USD Million)
4.2.4 Proton Therapy
4.2.4.1 Proton Therapy Market, 2018 - 2030 (USD Million)
4.2.4.2 Cyclotron
4.2.4.2.1 Cyclotron Market, 2018 - 2030 (USD Million)
4.2.4.3 Synchrotron
4.2.4.3.1 Synchrotron Market, 2018 - 2030 (USD Million)
4.3 Internal Beam Radiation Therapy
4.3.1 Internal Beam Radiation Therapy Market, 2018 - 2030 (USD Million)
4.3.2 Brachytherapy
4.3.2.1 Brachytherapy Market, 2018 - 2030 (USD Million)
4.3.2.2 Seeds
4.3.2.2.1 Seeds Market, 2018 - 2030 (USD Million)
4.3.2.3 Applicators And After-Loaders
4.3.2.3.1 Applicators And After-Loaders Market, 2018 - 2030 (USD Million)
4.3.2.4 Electronic Brachytherapy
4.3.2.4.1 Electronic Brachytherapy Market, 2018 - 2030 (USD Million)
4.3.3 Systemic Beam Radiation Therapy
4.3.3.1 Systemic Beam Radiation Therapy Market, 2018 - 2030 (USD Million)
4.3.4 Others
4.3.4.1 Others Market, 2016-2028 (USD Million)
Chapter 5 Radiation Oncology Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)
5.1 Radiation Oncology Market: Technology Movement Analysis
5.2 External Beam Radiation Therapy (EBRT)
5.2.1 EBRT Market, 2018 - 2030 (USD Million)
5.2.2 Image-Guided Radiation Therapy (IGRT)
5.2.2.1 IGRT Market, 2018 - 2030 (USD Million)
5.2.3 Intensity Modulated Radiotherapy (IMRT)
5.2.3.1 IMRT Market, 2018 - 2030 (USD Million)
5.2.4 Stereotactic Radiotherapy
5.2.4.1 Stereotactic Radiotherapy Market, 2018 - 2030 (USD Million)
5.2.5 Proton Beam Therapy
5.2.5.1 Proton Beam Therapy Market, 2018 - 2030 (USD Million)
5.2.6 3D Conformal Radiotherapy (3D-CRT)
5.2.6.1 3D-CRT Market, 2018 - 2030 (USD Million)
5.2.7 Volumetric Modulated Arc Therapy (VMAT)
5.2.7.1 VMAT Market, 2018 - 2030 (USD Million)
5.3 Brachytherapy
5.3.1 Brachytherapy Market, 2018 - 2030 (USD Million)
5.3.2 Low Dose Rate (LDR) Brachytherapy
5.3.2.1 LDR Brachytherapy Market, 2018 - 2030 (USD Million)
5.3.3 High Dose Rate (HDR) Brachytherapy
5.3.3.1 HDR Brachytherapy Market, 2018 - 2030 (USD Million)
Chapter 6 Radiation Oncology Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)
6.1 Radiation Oncology Market: Application Movement Analysis
6.2 External Beam Radiation Therapy (EBRT)
6.2.1 Prostate Cancer
6.2.1.1 Prostate Cancer Market, 2018 - 2030 (USD Million)
6.2.2 Breast Cancer
6.2.2.1 Breast Cancer Market, 2018 - 2030 (USD Million)
6.2.3 Lung Cancer
6.2.3.1 Lung Cancer Market, 2018 - 2030 (USD Million)
6.2.4 Head And Neck Cancer
6.2.4.1 Head And Neck Cancer Market, 2018 - 2030 (USD Million)
6.2.5 Colorectal Cancer
6.2.5.1 Colorectal Cancer Market, 2018 - 2030 (USD Million)
6.2.6 Others
6.2.6.1 Others Market, 2018 - 2030 (USD Million)
6.3 Internal Beam Radiation Therapy
6.3.1 Prostate Cancer
6.3.1.1 Prostate Cancer Market, 2018 - 2030 (USD Million)
6.3.2 Gynecologic Cancer
6.3.2.1 Gynecologic Cancer Market, 2018 - 2030 (USD Million)
6.3.3 Breast Cancer
6.3.3.1 Breast Cancer Market, 2018 - 2030 (USD Million)
6.3.4 Cervical Cancer
6.3.4.1 Cervical Cancer Market, 2018 - 2030 (USD Million)
6.3.5 Penile Cancer
6.3.5.1 Penile Cancer Market, 2018 - 2030 (USD Million)
6.3.6 Others
6.3.6.1 Others Market, 2018 - 2030 (USD Million)
Chapter 7 Radiation Oncology Market - Segment Analysis, By Region, 2018 - 2030 (USD Million)
7.1 Definition & Scope
7.2 North America
7.2.1 North America, SWOT Analysis
7.2.2 U.S.
7.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.2.2 Key Country Dynamics
7.2.2.3 Target Disease Prevalence
7.2.2.4 Competitive Scenario
7.2.2.5 Regulatory Framework
7.2.2.6 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.3.2 Key Country Dynamics
7.2.3.3 Target Disease Prevalence
7.2.3.4 Competitive Scenario
7.2.3.5 Regulatory Framework
7.2.3.6 Reimbursement Scenario
7.3 Europe
7.3.1 Europe, SWOT Analysis
7.3.2 U.K.
7.3.2.1 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.2.2 Key Country Dynamics
7.3.2.3 Target Disease Prevalence
7.3.2.4 Competitive Scenario
7.3.2.5 Regulatory Framework
7.3.2.6 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.3.2 Key Country Dynamics
7.3.3.3 Target Disease Prevalence
7.3.3.4 Competitive Scenario
7.3.3.5 Regulatory Framework
7.3.3.6 Reimbursement Scenario
7.3.4 France
7.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.4.2 Key Country Dynamics
7.3.4.3 Target Disease Prevalence
7.3.4.4 Competitive Scenario
7.3.4.5 Regulatory Framework
7.3.4.6 Reimbursement Scenario
7.3.5 Italy
7.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.5.2 Key Country Dynamics
7.3.5.3 Target Disease Prevalence
7.3.5.4 Competitive Scenario
7.3.5.5 Regulatory Framework
7.3.5.6 Reimbursement Scenario
7.3.6 Spain
7.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.6.2 Key Country Dynamics
7.3.6.3 Target Disease Prevalence
7.3.6.4 Competitive Scenario
7.3.6.5 Regulatory Framework
7.3.6.6 Reimbursement Scenario
7.3.7 Sweden
7.3.7.1 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.7.2 Key Country Dynamics
7.3.7.3 Target Disease Prevalence
7.3.7.4 Competitive Scenario
7.3.7.5 Regulatory Framework
7.3.7.6 Reimbursement Scenario
7.3.8 Denmark
7.3.8.1 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.8.2 Key Country Dynamics
7.3.8.3 Target Disease Prevalence
7.3.8.4 Competitive Scenario
7.3.8.5 Regulatory Framework
7.3.8.6 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.9.2 Key Country Dynamics
7.3.9.3 Target Disease Prevalence
7.3.9.4 Competitive Scenario
7.3.9.5 Regulatory Framework
7.3.9.6 Reimbursement Scenario
7.3.10 Rest Of Europe
7.3.10.1 Rest Of Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific, SWOT Analysis
7.4.2 India
7.4.2.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.2.2 Key Country Dynamics
7.4.2.3 Target Disease Prevalence
7.4.2.4 Competitive Scenario
7.4.2.5 Regulatory Framework
7.4.2.6 Reimbursement Scenario
7.4.3 China
7.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.3.2 Key Country Dynamics
7.4.3.3 Target Disease Prevalence
7.4.3.4 Competitive Scenario
7.4.3.5 Regulatory Framework
7.4.3.6 Reimbursement Scenario
7.4.4 Japan
7.4.4.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.4.2 Key Country Dynamics
7.4.4.3 Target Disease Prevalence
7.4.4.4 Competitive Scenario
7.4.4.5 Regulatory Framework
7.4.4.6 Reimbursement Scenario
7.4.5 Australia
7.4.5.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.5.2 Key Country Dynamics
7.4.5.3 Target Disease Prevalence
7.4.5.4 Competitive Scenario
7.4.5.5 Regulatory Framework
7.4.5.6 Reimbursement Scenario
7.4.6 South Korea
7.4.6.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.6.2 Key Country Dynamics
7.4.6.3 Target Disease Prevalence
7.4.6.4 Competitive Scenario
7.4.6.5 Regulatory Framework
7.4.6.6 Reimbursement Scenario
7.4.7 THAILAND
7.4.7.1 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.7.2 Key Country Dynamics
7.4.7.3 Target Disease Prevalence
7.4.7.4 Competitive Scenario
7.4.7.5 Regulatory Framework
7.4.7.6 Reimbursement Scenario
7.4.8 Rest Of APAC
7.4.8.1 Rest Of APAC Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America, SWOT Analysis
7.5.2 Mexico
7.5.2.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5.2.2 Key Country Dynamics
7.5.2.3 Target Disease Prevalence
7.5.2.4 Competitive Scenario
7.5.2.5 Regulatory Framework
7.5.2.6 Reimbursement Scenario
7.5.3 Brazil
7.5.3.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5.3.2 Key Country Dynamics
7.5.3.3 Target Disease Prevalence
7.5.3.4 Competitive Scenario
7.5.3.5 Regulatory Framework
7.5.3.6 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5.4.2 Key Country Dynamics
7.5.4.3 Target Disease Prevalence
7.5.4.4 Competitive Scenario
7.5.4.5 Regulatory Framework
7.5.4.6 Reimbursement Scenario
7.5.5 Rest Of LATAM
7.5.5.1 Rest Of LATAM Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 Middle East & Africa, SWOT Analysis
7.6.2 South Africa
7.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.2.2 Key Country Dynamics
7.6.2.3 Target Disease Prevalence
7.6.2.4 Competitive Scenario
7.6.2.5 Regulatory Framework
7.6.2.6 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.3.2 Key Country Dynamics
7.6.3.3 Target Disease Prevalence
7.6.3.4 Competitive Scenario
7.6.3.5 Regulatory Framework
7.6.3.6 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.4.2 Key Country Dynamics
7.6.4.3 Target Disease Prevalence
7.6.4.4 Competitive Scenario
7.6.4.5 Regulatory Framework
7.6.4.6 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.5.2 Key Country Dynamics
7.6.5.3 Target Disease Prevalence
7.6.5.4 Competitive Scenario
7.6.5.5 Regulatory Framework
7.6.5.6 Reimbursement Scenario
7.6.6 Rest Of MEA
7.6.6.1 Rest Of MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Public Companies
8.1.1 Company Market Position Analysis
8.1.2 Competitive Dashboard Analysis
8.1.3 Strategic Framework
8.2 Private Companies
8.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
8.2.2 Regional Network Map
8.3 Company Profiles
8.3.1 Varian Medical Systems, Inc. (A Part Of Siemens Healthineers)
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Elekta AB
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Accuray Incorporated
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Ion Beam Applications (IBA).
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 BD (Becton, Dickinson And Company)
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Isoray Medical
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Mevion Medical Systems
8.3.7.1 Company Overview
8.3.7.2 Product Benchmarking
8.3.7.3 Strategic Initiatives
8.3.8 Nordion Inc.
8.3.8.1 Company Overview
8.3.8.2 Product Benchmarking
8.3.8.3 Strategic Initiatives
8.3.9 NTP Radioisotopes SOC Ltd.
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Curium
8.3.10.1 Company Overview
8.3.10.2 Product Benchmarking
8.3.10.3 Strategic Initiatives
8.3.11 VIEWRAY TECHNOLOGIES, INC.
8.3.11.1 Company Overview
8.3.11.2 Financial Performance
8.3.11.3 Product Benchmarking
8.3.11.4 Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings